Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002568705 | SCV003010308 | likely benign | Dyskeratosis congenita, autosomal dominant 2; Idiopathic Pulmonary Fibrosis | 2023-03-31 | criteria provided, single submitter | clinical testing | |
Johns Hopkins Genomics, |
RCV003229617 | SCV003927235 | uncertain significance | Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1 | 2023-03-13 | criteria provided, single submitter | clinical testing | This TERT missense variant (rs1169312254) is rare (<0.1%) in a large population dataset (gnomAD v2.1.1: 2/279758 total alleles; 0.0007%; no homozygotes). It has been reported in ClinVar (Variation ID 973676) but has not been reported in the literature, to our knowledge. Two bioinformatic tools queried predict that this substitution would be tolerated, and the aspartic acid residue at this position is evolutionarily conserved across many of the species assessed, but several species have a different amino acid this position including some species with asparagine. We consider the clinical significance of c.2419G>A; p.Asp807Asn in TERT to be uncertain at this time. |
Ambry Genetics | RCV004822340 | SCV005512370 | uncertain significance | Dyskeratosis congenita | 2024-10-21 | criteria provided, single submitter | clinical testing | The p.D807N variant (also known as c.2419G>A), located in coding exon 8 of the TERT gene, results from a G to A substitution at nucleotide position 2419. The aspartic acid at codon 807 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
UOSD Laboratory of Genetics & Genomics of Rare Diseases, |
RCV001267800 | SCV001424118 | uncertain significance | Dyskeratosis congenita, autosomal dominant 2 | 2020-05-21 | no assertion criteria provided | clinical testing |